# Krebs Biochemicals and Industries (NSE: KREBSBIO) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/KREBSBIO · Pivot · prices to 22 Oct 2026

Krebs Biochemicals and Industries (NSE: KREBSBIO) closed at ₹56.59 on 22 Oct 2026, up 0.78% on the day. With a market capitalisation of ₹122 Cr, it ranks 2547th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.

Its return on equity was 0.0% in FY26. Over the past year the share price has fallen 19.3%. Its 52-week range is ₹38.33 (30 Mar 2026) to ₹76.85 (5 Dec 2025); the last close is 26.4% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹7 Cr (+27.4% year on year) and net profit −₹2 Cr, on a standalone basis. Promoters held 72.74% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹56.59 |
| Market cap | ₹122 Cr |
| ROE | 0.0% (FY26) |
| ROCE | −19.6% (FY26) |
| Debt to equity | -1.38 |
| 52-week high | ₹76.85 (5 Dec 2025) |
| 52-week low | ₹38.33 (30 Mar 2026) |
| 1-year return | −19.3% |

## Quarterly results (₹ crore, standalone)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q1 FY27 | ₹7 Cr | +27.4% | −₹2 Cr | — | −₹1.15 |
| Q4 FY26 | ₹7 Cr | +11.6% | −₹2 Cr | — | −₹1.09 |
| Q3 FY26 | ₹7 Cr | −36.6% | −₹3 Cr | — | −₹1.45 |
| Q2 FY26 | ₹4 Cr | −67.6% | −₹6 Cr | — | −₹2.85 |
| Q1 FY26 | ₹5 Cr | −57.5% | −₹5 Cr | — | −₹2.47 |
| Q4 FY25 | ₹6 Cr | −49.0% | −₹8 Cr | — | −₹3.83 |
| Q3 FY25 | ₹11 Cr | −11.6% | −₹8 Cr | — | −₹3.59 |
| Q2 FY25 | ₹13 Cr | −13.6% | −₹6 Cr | — | −₹2.67 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹43 Cr | −₹27 Cr |
| FY24 | ₹50 Cr | −₹20 Cr |
| FY23 | ₹52 Cr | −₹25 Cr |
| FY22 | ₹60 Cr | −₹45 Cr |
| FY21 | ₹54 Cr | −₹28 Cr |
| FY20 | ₹33 Cr | −₹29 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 72.74%
- Foreign institutions: 0.50%
- Non-institutions: 26.76%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Lactose India](https://app.pivotnow.in/stock/LACTOSE) | — | ₹132 Cr | — | — |
| [Valencia Nutrit](https://app.pivotnow.in/stock/VALENCIA) | — | ₹132 Cr | — | — |
| [Par Drugs And Chemicals](https://app.pivotnow.in/stock/PAR) | ₹102.90 | ₹127 Cr | 9.7 | — |
| [Aspira Pathlab](https://app.pivotnow.in/stock/ASPIRA) | — | ₹125 Cr | — | — |
| [Godavari Drugs](https://app.pivotnow.in/stock/GODAVARI) | — | ₹120 Cr | — | — |
| [Parnax Lab](https://app.pivotnow.in/stock/PARNAXLAB) | ₹104.00 | ₹119 Cr | 10.1 | — |

## Questions and answers

### What is the share price of Krebs Biochemicals and Industries today?

Krebs Biochemicals and Industries (NSE: KREBSBIO) last closed at ₹56.59 on 22 Oct 2026. Its 52-week high is ₹76.85 and its 52-week low is ₹38.33.

### What is the market cap of Krebs Biochemicals and Industries?

Krebs Biochemicals and Industries' market capitalisation is ₹122 Cr (₹122 Cr) at the 22 Oct 2026 close, ranking 2547th among the NSE companies Pivot tracks.

### What is the ROE and ROCE of Krebs Biochemicals and Industries?

Return on equity was 0.0% in FY26 and return on capital employed was −19.6% in FY26 (standalone figures).

### Is Krebs Biochemicals and Industries a debt-free company?

Krebs Biochemicals and Industries is close to debt-free: its debt-to-equity ratio was -1.38 in FY26.

### What were Krebs Biochemicals and Industries' latest quarterly results?

For Q1 FY27 (quarter ended 30 Jun 2026), Krebs Biochemicals and Industries reported revenue of ₹7 Cr, +27.4% year on year, and net profit of −₹2 Cr.

### How has Krebs Biochemicals and Industries stock performed over the last year?

Krebs Biochemicals and Industries' share price has fallen 19.3% over the past year, +6.0% over three months and +0.6% over one month, to the 22 Oct 2026 close.

### What is the shareholding pattern of Krebs Biochemicals and Industries?

As of 30 Jun 2026: promoters 72.74%, foreign institutions 0.50%, non-institutions 26.76%.

### Who are Krebs Biochemicals and Industries' competitors?

The listed Pharma & Healthcare companies closest to Krebs Biochemicals and Industries by market cap are Lactose India, Valencia Nutrit, Par Drugs And Chemicals, Aspira Pathlab, Godavari Drugs and Parnax Lab.

### Is Krebs Biochemicals and Industries a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Krebs Biochemicals and Industries' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on KREBSBIO against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.